Loading stock…

Organon & Co. (OGN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Organon & Co.

OGNMarket cap $3.61BPrice $13.7

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Makes and sells women's health drugs, biosimilars, and established medicines spun off from Merck in 2021. Runs one of the largest standalone portfolios focused entirely on women's health, treating millions worldwide despite being a relatively young public company.

In Bastion Portfolios?

52W Return+49%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+0%3

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+1%1

Rev CAGR (5y)+1%1

Earnings Forecast

EPS Growth Y+1+2%4

EPS Growth Y+2+7%6

EPS Growth Y+3+6%6

Quality

Margins

EBIT Margin20%7

Net Income Margin3%3

Free Cash Flow Margin9%6

Debt

Net Debt/EBITDA4.52

Efficiency

ROE24%8

ROA2%3

Earnings Stability22

GEAR+WEAK19

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)410

P/E Ratio (Forward 3y)410

P/BV3.64

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd610

Yield

Free Cash Flow Yield15.7%10

Dividend Yield0.6%2

Momentum

Short term

1 month return-0%8

3 month return+2%7

YTD return+93%10

Mid term

Price vs 52wHigh100%10

1 year return+31%8

Long term

3 year return-7%2

5 year return-49%1

Risk Shield

Price Risk

Beta0.94

Volatility63%2

Free Cash Flow

Free Cash Flow Margin9%6

Free Cash Flow Yield15.7%10

Quality

ROCE11%6

Earnings Stability22

Net Debt/EBITDA4.52

02Growth

Is it actually growing, and how fast?

OGNOrganon &

Revenue FY25$6.4B

GROWTH RATING↗

VERY WEAK4 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+0%3

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+1%1

Revenue, next 5Y, CAGR+1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+2%4

EPS growth, FY27E+7%6

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 6%/yr vs revenue 0.8%/yr), so margins should widen.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0.8%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 96% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 0.8%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to grow 0.9%/yr, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+2%7

YTD return+93%10

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+31%8

3-year return-7%2

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 31% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+2%) and so far this year (+93%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-6.9% over three years and -49% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Organon & Co.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

OGNOrganon &

Revenue FY25$6.4B

GROWTH RATING↗

VERY WEAK4 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+0%3

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+1%1

Revenue, next 5Y, CAGR+1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+2%4

EPS growth, FY27E+7%6

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 6%/yr vs revenue 0.8%/yr), so margins should widen.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0.8%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 96% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 0.8%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to grow 0.9%/yr, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the 3-year revenue record is weak.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE62 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+2%7

YTD return+93%10

MID & LONG-TERM▾SCORE

% of 52-week high100%10

1-year return+31%8

3-year return-7%2

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 31% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+2%) and so far this year (+93%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-6.9% over three years and -49% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Organon & Co.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community